The mineralocorticoid receptor (MR) is unique in responding to 2 physiological ligands: aldosterone and cortisol. In epithelial tissues, aldosterone selectivity is determined by the activity of 11␤-hydroxysteroid dehydrogenase type 2. In other tissues, cortisol is the primary ligand. To understand the structural determinants of ligand-specific MR activation, we sought to identify coregulatory molecules that interact with the ligand-binding domain ( 
The aldosterone or mineralocorticoid receptor (MR) plays a central role in the pathophysiology of both cardiac failure and hypertension through effects on sodium homeostasis and on the vascular system (1, 2) . The MR is also found in the central nervous system, where it plays a role in neuronal survival, cognition, memory, and the central regulation of blood pressure (1, 3) . The role of the MR in cardiac function has been the focus of considerable recent attention, largely as a result of the landmark Randomized Aldactone Evaluation Study (RALES), Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS), and Eplerenone in Mild Patients Hospitalization and Survival Study (EMPHASIS) trials (4) . In these studies, the addition of the MR antagonists spironolactone or eplerenone to standard therapy substantially reduced both morbidity and mortality in patients with severe or mild cardiac failure, respectively. Other studies have shown beneficial effects on cardiac function, diastolic dysfunction, and proteinuria, independent of effects on blood pressure (5) . This impressive therapeutic benefit with MR antagonists is limited by the development of hyperkalemia in Ͼ10% of patients (5, 6) . Hyperkalemia results from blockade of the MR in epithelial tissues (kidney, colon). There is clearly a need for the development of tissue-specific MR antagonists for use in cardiovascular and cerebrovascular disease. Although there is ample precedent for the development of tissue-specific steroid receptor ligands, before they can be developed for the MR, a much greater understanding of MR function, particularly the mechanisms of ligand discrimination, is needed.
The MR is a member of the nuclear hormone receptor superfamily of ligand-activated transcription factors (7, 8) and is unique in that it operates under physiological conditions as a receptor for 2 classes of steroid hormone: mineralocorticoids (aldosterone) and glucocorticoids (cortisol or corticosterone in rodents) (1, 8) . Steroid hormone receptors have a mod-ular structure with 3 major functional domains: the N-terminal domain, the central DNA-binding domain, and the ligand-binding domain (LBD). Binding of ligand creates distinct conformational changes in the LBD that have critical consequences for the subsequent interactions of the receptor. Transcriptional activation, the principal signaling mode for these receptors, is mediated by 2 physically distinct activation functions (AF-1 and AF-2), which interact with coregulatory molecules and the basal transcriptional apparatus. AF-1 is in the N-terminal domain, and its activity is ligand independent, whereas AF-2 in the LBD requires ligand binding to achieve its active conformation (7) .
Nuclear hormone receptors act as tethers for the host of other nuclear proteins that regulate RNA transcription (7) . The coregulators enhance (coactivators) or repress (corepressors) transcription. Most coactivators interact with agonist-bound receptors and with other transcription factors (7, 9) . The p160 family [steroid receptor coactivator 1-3 (SRC-1-3)] interacts with the AF-2 region of the MR (10 -12) . Targeted gene deletion studies in mice suggest that p160 coactivators are not critical for MR function, as neither a double SRC-1/SRC-2-knockout mouse (13) nor an SRC-3-knockout mouse (14) exhibits the profound salt-wasting and dehydration observed in the MR-knockout mouse (15) . Peroxisome proliferation activator receptor ␥ (PRAR␥) coactivator 1␣ (PGC-1␣) has been shown to enhance MR function in vitro (16) . However, in the mouse kidney, it is not found in MR-expressing cortical collecting tubules (17) . Well over 300 other coregulators have been described to date (9, 18, 19) ; most of these are poorly characterized, and almost none have been studied in the context of the MR. Only a few studies have screened for MR-specific coregulatory molecules (20 -26) . These studies, with 2 exceptions, used MR N-terminal fragments in yeast-2 hybrid (Y2H) screens. A small ubiquitin-like modifier 1 (SUMO-1) E3, PIAS1; a SUMO-1 conjugation enzyme, Ubc9; a ubiquitous transcription factor, NF-YC; and 3 homologues of apoptosis genes were isolated. In all of these studies, neither tissue nor ligand specificity was identified. A study reporting that the RNA polymerase II elongation factor RNA helicase A is a ligand-specific MR coactivator has recently been retracted (27) .
The interaction of most coactivators with nuclear receptors involves 1 or more leucine-x-x-leucine-leucine (LxxLL; where x is any amino acid) motifs that bind to the AF-2 region of the LBD. Hultman et al. (28) and Li et al. (29) examined, respectively, 50 and 38 LxxLL motifs from known coregulators for an interaction with the MR-LBD. Hultman et al. (28) found that only LxxLL motifs from SRC-1 and PGC-1␣ interacted with the MR-LBD in a mammalian-2-hybrid (M2H) assay; Li et al. (29) used an ␣ screen to identify a small number of additional interactions. Again, in neither study was ligand discrimination identified.
Natural glucocorticoids may be MR ligands that function in a manner that is analogous to that of the selective estrogen receptor modulators (SERMs), as tissue-specific agonists or antagonists. In epithelial cells of the kidney and colon (1) and in vascular smooth muscle cells (1, 2) , both aldosterone and cortisol can act as MR agonists. In these cells, specificity is maintained by the actions of 11␤-hydroxysteroid dehydrogenase type 2 (11␤HSD2; ref. 30) . In nonepithelial cells, such as neurons and cardiomyocytes, 11␤HSD2 protection is absent, and glucocorticoids can bind to the MR and antagonize the effects of aldosterone (31) (32) (33) . The mechanisms that underlie this tissue-specific difference remain to be determined, but some clues have emerged. Evidence of a difference between aldosterone and cortisol at a molecular level is provided by our findings that, although aldosterone promotes an interaction between the N terminus and the LBD of the MR (N/C interaction) in an M2H assay (34, 35) , cortisol is only a weak agonist and acts as an antagonist in the presence of aldosterone in this assay. Analysis of ligand binding to chimeras created between the MR and the glucocorticoid receptor (GR) LBD indicated that interactions of cortisol and aldosterone with the MR are not equivalent (36, 37) . Mutational analysis of the MR has identified differences in the coactivator binding grooves induced by aldosterone and cortisol, although the investigators were unable to identify differential interactions with the known coactivators (38) . Finally, we used phage display to identify 19-mer peptides that interact with full-length MR in a ligand-dependent manner (39) . These observations strongly support the concept of ligand-specific interactions.
In this study, we sought to identify coregulatory molecules that exhibit a ligand-specific interaction with the MR. Given that the previous studies seeking MRinteracting molecules had generally used the N-terminal domain, and given that a ligand-specific interaction would seem more likely to involve the LBD, we screened 2 Y2H cDNA libraries with the MR-LBD in the presence of aldosterone and cortisol. We report the identification of the human homologue of a known mouse gene, tesmin, as being a ligand-discriminant coactivator of human MR (hMR).
MATERIALS AND METHODS

Y2H screen
The Y2H screen was performed with the Matchmaker TwoHybrid System 3 (Clontech, Palo Alto, CA, USA), according to the manufacturer's protocol. hMR-LBD was PCR amplified, with pRShMR as the template, and subcloned into the pGBKT7 vector. This bait vector was transfected into the AH109 (MAT␣) yeast strain and grown in the absence of tryptophan. The integrity of MR-LBD expressed in yeast was confirmed with the 3 H-aldosterone whole-cell binding assay. Two Matchmaker GAL4 cDNA libraries (human kidney and heart) cloned into the pACT2 vector (Clontech) in the Y187 (MAT␣) yeast strain were screened. Before screening, mating efficiency was tested with MRLBD (AH109) with the P/Control (Y187), to establish that the MRLBD construct did not affect mating efficiency. The bait-and library-containing yeast strains were mated and plated on histidine (His)-, leucine (Leu)-, and tryptophan (Trp)-deficient plates in the presence of X-␣-Gal and 1 M aldosterone or 1 M cortisol. To increase the stringency of the screen, positive colonies were replated on His-, adenine (Ade)-Leu-, and Trp-deficient plates in the presence of X-␣-Gal and 1 M aldosterone or 1 M cortisol. Positive clones were tested for ␤-galactosidase activity in the presence of aldosterone or cortisol, and plasmid DNA was isolated for amplification of the cDNA insert, with the primers Y2H-AD-5 and Y2H-AD03 (Clontech). The PCR product was ligated in pGEM-T Easy vector (Promega, Madison, WI, USA) for sequence analysis at the Gandel Charitable Trust Sequencing Centre (Clayton, VIC, Australia) with a T7 primer. Inserts were subcloned into the pVP16 vector for analysis in an M2H assay with the MR-LBD (33, 34) .
Cell culture and mammalian-2-hybrid assays
The M2H assays were performed in COS-1 cells cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 1 mM glutamine, nonessential amino acids, 0.075% sodium bicarbonate, 10 mM HEPES, and penicillin (10 IU/L)-streptomycin (10 g/L) in 5% CO 2 (34, 35) . The cells were trypsinized and seeded at a density of 8 ϫ 10 4 cells/well in 12-well plates in DMEM supplemented with 10% FBS. The cells were incubated overnight before transfection. An insert encoding PGC-1␣ (amino acids 33-361), isolated in the Y2H screen, was subcloned as above and used as a positive control in the M2H assay. Transfections were performed with Fugene 6 (Roche Molecular Biochemicals, Indianapolis, IN, USA), per the manufacturer's protocol; the medium was changed to DMEM supplemented with 5% charcoal-stripped serum; and the cells were incubated for 24 h. The transfected cells were then treated with steroids and incubated for a further 24 h and harvested for luciferase (LUC) analysis. LUC activity was assayed with the Luclite kit (Perkin Elmer, Waltham, MA, USA), according to the manufacturer's instructions. Briefly, the cells were washed once in PBS supplemented with 0.5 mM MgC1 2 and 0.5 mM CaCl 2 and resuspended in 100 l of supplemented PBS with 100 l of Luclite substrate buffer. The cell lysates were transferred to a 96-well plate, and relative light units were measured for 1 s in a luminometer (2103 Lumicount; Perkin Elmer). All assays were performed in triplicate in 2 independent experiments.
Transactivation assay
The tesmin expression vector was constructed by amplifying 2 fragments from human testis RNA (kindly provided by Dr. Moira O'Brien, Monash University, Clayton, VIC Australia). The two amplicons spanned an XbaI restriction site present in the published tesmin cDNA sequence (NM_004923). The primers used were as follows: forward, 5=-CCGGGTACCGC-CATGGAGGAGGGCCCTCTG (start codon at 155 is in italics; the added KpnI site is underscored), and reverse, 5=-TGCTTT-TAGTTCTCTTGTTCTA (internal XbaI site at 833 is underscored); and forward, 5=-TTAAGAAAGATTCCAACCCAAT (aa 762), and reverse, 5=-CACTTTATCTCGAGCTCCA-TTTTCAATCCCTTAG (aa 1664; added XhoI site is underscored). The amplified fragments were initially subcloned into the KpnI and XhoI sites of pcDNA3.1/myc-HisA, but the vector alone exhibited a high background in the transactivation assay, so the full-length tesmin cDNA was then subcloned into pSG5-HAb (kindly provided by Dr. Martin Privalsky, University of California, Davis, CA, USA). The tesmin isoform b expression vector was created by using the full-length construct as the template for amplification, with the forward primer as above and the reverse primer 5=GGCAAAGCACTC-GAGATTACCCAGCCAAGTTATTTTTGG (stop codon is in italics; Xhol site is underscored). The amplifying fragment was restricted with Kpnl and Xhol and then subcloned into pSG5-HAb. Expression vectors for human SRC-1e and PGC-1␣ were constructed in the same vector from existing plasmids. hMR expression, MMTV-LUC reporter, and Renilla-LUC (Ren-LUC) control plasmids have been described previously (36, 37) . The glucocorticoid-induced leucine zipper (GILZ)-LUC and connector enhancer of kinase suppressor of Ras isoform 3 (CNKSR3)-LUC reporters have been previously described (40) . CV-1 African green monkey cells were grown at 37°C in DMEM (supplemented with 0.075% sodium bicarbonate, 10 mM HEPES, 1 mM glutamine, nonessential amino acids, penicillin (10 IU/L)-streptomycin (10 g/L), fungizone (0.025 g/L Life Technologies, Carlsbad, CA, USA), and 10% FBS. The cells were trypsinized and replated in 24-well plates at a density of 5 ϫ 10 4 cells/well in DMEM ϩ 5% FBS. After 24 h, the cells were transfected with 0.25 g of the coregulator expression plasmid, 0.25 g of the MMTV-LUC reporter plasmid, 0.25 g of pRShMR, and 0.25 g of the pRen-LUC control plasmid, with Fugene 6 (Roche Applied Science), per the manufacturer's protocol, and the medium was changed to DMEM supplemented with 5% charcoalstripped FBS. The cells were then incubated at 37°C for 24 h. Fresh DMEM ϩ 5% charcoal-stripped FBS was added to the cells before addition of the steroid. The cells were incubated with the steroid for 24 h at 37°C and then harvested for assay. Measurement of transactivation was performed with the DualLuciferase Reporter Assay kit (Promega). The cells were incubated with 100 l lysis buffer for 15 min at room temperature. A 20 l aliquot was removed to a 96-well plate for assay, and relative light units were measured for 1 s in the Lumicount luminometer (PerkinElmer). Renilla LUC activity was determined as a control for transfection efficiency. All measurements were performed in 3 replicates in Ն2 separate experiments.
Mutagenesis
Point mutations were incorporated into both LxxLL motifs, alone and together, in both the pVP16 vector containing tesmin 16 -243 and the pSG5-HA expression vector containing full-length tesmin. The LxxLL motifs were mutated to LxxAA (38, 41) using the QuickChangeII Site-Directed Mutagenesis Kit (Stratagene, La Jolla, CA, USA), per the manufacturer's instructions. The primers used for the mutagenesis are presented in Supplemental Data. Successful mutagenesis was confirmed by direct sequencing.
Coimmunoprecipitation (co-IP)
Co-IP experiments were performed in COS-1 African green monkey kidney cells cultured in DMEM supplemented with 10% FBS, 1 mM glutamine, nonessential amino acids, 0.075% sodium bicarbonate, 10 mM HEPES, and penicillin (10 IU/L)-streptomycin (10 g/L) in 5% CO 2 . The cells were seeded at a density of 2 ϫ 10 5 cells/well in 6-well plates in DMEM supplemented with 10% FBS and incubated 24 h before transfection with 2 g pRShMR and 2 g coregulator expression plasmids. Transfections were performed with Fugene 6 (Roche), and the medium was changed to fresh DMEM supplemented with 10% FBS. After transfection, the cells were incubated for 24 h before being treated with 1 M aldosterone or cortisol and then harvested with the ProFound Mammalian Co-Immunoprecipitation Kit (Thermo ScientificPierce, Rockford, IL, USA) as per the manufacturer's instructions. Cell lysates were incubated with rat monoclonal anti-HA High-Affinity antibody (Roche Applied Science) coupling gel for 1-2 h. Potential antibody-antigen protein complexes were eluted and then subjected to SDS-PAGE and Western blot analysis with mouse monoclonal antibody MR1-18 (a gift from Prof. Celso Gomez-Sanchez, University of Mississippi Medical Center, Jackson, MS, USA). The membrane was incubated with horseradish peroxidase-linked antimouse secondary antibody (Dako, Carpinteria, CA, USA; 1:1000) for 60 min at room temperature. Antibody binding was visualized by chemiluminescence with the Amersham ECL Plus Western Blot Detection System (GE Healthcare, Little Chalfont, UK). pSG5-HAb vector alone and pSG5-HAb-PGC-1␣ were used as negative and positive controls, respectively.
RESULTS
The Y2H screen of a human kidney cDNA library, using the hMR-LBD as bait, identified 56 ligand-dependent interactants, including fragments encoding SRC-1 and PGC-1␣. Of these clones, 6 exhibited an interaction in the presence of aldosterone (1 M), but not of cortisol (1 M) , in a plate screen. The cDNA inserts from these 6 clones were then examined in an M2H assay. In contrast to the yeast screen, all 6 showed an interaction with the hMR-LBD in the presence of both aldosterone and cortisol. In all cases, the interaction was dependent on an intact AF-2 region, as it was not observed when the M2H assay was conducted with the hMR-LBD (E962A). This mutation has been shown to selectively inactivate the AF-2 function (20, 34) . The interaction of steroids with their receptors may vary somewhat in yeast from mammalian cells (42, 43) , which can be a result of steroid efflux from the cell by a yeast ATP-binding cassette transporter (44) . This effect is unlikely to be relevant in this work, given that the SRC-1 and PGC-1␣ clones showed a robust interaction with the MR-LBD in the presence of cortisol. The interaction between PGC-1␣ and the hMR-LBD in the M2H assay was essentially equivalent for aldosterone and cortisol, so the response with PGC-1␣ was used as the denominator to compare the relative responses of each of the clones. We identified one clone that interacted with the MR-LBD 7 times more potently in the presence of aldosterone (100 nM) than with cortisol (100 nM) (Fig. 1) .
This clone, derived from the Y2H human kidney cDNA library, represents nt 186 -869 of the human cDNA (NM_004923) that encodes the human homologue of the mouse tesmin gene, also known as testisspecific, metallothionein-like 5 (MTL5). The fragment encodes aa 16 -243, which includes 2 LxxLL motifs (Fig. 2) . Tesmin is an MTL protein that was originally identified as a testis-and ovary-specific gene in mice (44) and has subsequently been found at low frequency in many human tissues as an expressed sequence tag (EST). Two transcript variants have been reported that encode isoforms that differ at their C termini. Both variants include the sequence encoded by this clone. To establish whether tesmin is indeed an MR coregulatory molecule, we examined the interaction between full-length tesmin and the hMR in a transactivation assay using CV-1 cells that do not express endogenous tesmin (Supplemental Fig. S1 ). Cotransfection with tesmin yielded a Ͼ2-fold enhancement of the liganddependent transactivation of the MR (Fig. 3) . As expected (16), coactivation was also seen with PGC-1␣ (Supplemental Fig. S2 ) in the presence of aldosterone. This was not the case with cortisol, where coactivation was observed for PGC-1␣ but not with tesmin. The dose-response curve with aldosterone for tesmin-medi- ated coactivation of the MR does not differ from the EC 50 for aldosterone with the empty vector control (Supplemental Fig. S3 ), nor is this differential ligandspecific response a consequence of a ligand-or tesmininduced change in MR levels (Supplemental Fig. S4 ). The MR-LBD sequence shares Ͼ50% amino acid sequence identity with the androgen receptor (AR), the progesterone receptor (PR), and the GR; and ϳ30% with the estrogen receptor (ER) (8) . Given that tesmin has been identified through its interactions with the MR-LBD, we sought to determine the receptor specificity of the interaction. The AR, PR, GR, and ER␣ were transfected into CV-1 cells with the appropriate reporters MMTV-LUC (PR and GR), ERE-LUC (ER␣), and AR (ARA3-tk-LUC) in the presence of their respective ligands (Fig. 4) . As expected, all exhibited liganddependent coactivation with SRC-1e, as did the MR. Tesmin acted as a coactivator for the AR only with no coactivation of the GR, ER␣, or PR when analyzed as the fold change over baseline in the absence of ligand.
Although spironolactone is an MR antagonist, it has very weak partial agonist activity that can be observed in vitro (45, 46) . The consequences of tesmin cotransfection with the MR in the presence of spironolactone was therefore examined (Fig. 5A) . Tesmin significantly enhanced the very weak agonist activity of spironolactone. However, tesmin did not, in this context, alter the predominant antagonist properties of spironolactone. In view of the ligand-dependence of the interaction, we examined another physiological ligand for the MR, deoxycorticosterone (DOC). As with aldosterone and in contrast to cortisol, tesmin coactivated the MR in the presence of DOC (Fig. 5B) .
In addition to both the ligand and cell dependence of coregulatory molecules, their effect on nuclear receptors may also be context dependent. The above studies involved the widely used MMTV promoter, a complex promoter containing multiple response elements (47) . To address promoter dependence, we examined 2 physiologically relevant promoters (40) from the human GILZ and CNKSR3 genes (Fig. 6) . Cotransfection with tesmin significantly increased aldosterone-induced but not cortisol-induced transactivation at the GILZ and CNKSR3 promoters.
The role of the 2 LxxLL motifs in tesmin were examined in both the M2H assay and in the cotransfection assay (Fig. 7) . In each case, the first, second, or both motifs were inactivated by mutating them to LxxAA (38, 41) . The positions of the structural motifs and the mutations in tesmin are shown schematically in (Fig. 7) is attenuated, with each motif mutated individually and completely lost when both motifs are mutated. The interaction with the double mutant was significantly lower than that with vector alone, indicating a ligand-dependent interference in the assay. The Western blot analysis confirmed that this is not an effect of the mutation on tesmin stability. Coactivation of ligand-dependent, MR-mediated transactivation (Fig.  7) was similarly compromised. Mutation of either LxxLL motif eliminated MR-mediated coactivation. With both motifs mutated, the construct has an inhibitory effect on both aldosterone-and cortisol-mediated responses of the MR. The Western blot analysis confirmed that the mutations do not alter the stability of the HA-tagged tesmin.
To formally demonstrate that tesmin interacts with the MR, we performed co-IP with the empty pSG5 HA vector, PGC-1␣, and tesmin, taking advantage of the HA tag in the vector. Immunoblot analysis with an MR antibody demonstrated that both PGC-1␣ and tesmin pulled down the MR in the presence of aldosterone, whereas the vector alone did not (Fig. 8) . An interaction is not seen in the presence of cortisol (Fig. 8) . As was observed in the M2H assay (Fig. 8) , an aldosteronedependent interaction is observed when either LxxLL motif alone is mutated to LxxAA, but not when both are mutated (Fig. 8) . That this is a direct interaction was further confirmed with a GST-pulldown assay (Supplemental Fig. S5 ).
As noted, tesmin is also expressed as a shorter second isoform of 306 aa. Isoform b arises through alternative splicing and results in termination of the protein before the tesmin/TS01-like CXC domain. Isoform b contains both LxxLL motifs. Tesmin isoform b was examined as for isoform a (Fig. 3) in the transactivation assay (Fig. 9) . Isoform b shows an equivalent level of ligand-specific transactivation to that seen with the longer isoform. The CXC domain therefore appears not to be essential for the coactivation.
DISCUSSION
The identification of differential ligand-specific differences in the response to nuclear receptor activation has important therapeutic implications. Ligand-selectivity of receptor activation has been reported for the ER (7), GR (48), AR (49) , and PR (50) by so-called selective receptor modulators. These agents exploit different mechanisms to enrich antagonist actions in breast (tamoxifen), achieve greater anabolic than androgenic activation of the AR (49), provide immunosuppression without the metabolic consequences of GR activation (48) , and treat uterine pathology without the adverse side effects of PR activation (50) . In each case, ligand discrimination is a result of differential interaction of cell-or stimulus-specific proteins with the activated receptor. These molecules include both coregulators and other transcription factors. Although the currently available MR antagonists spironolactone and eplerenone have been shown to provide significant therapeutic benefit in cardiovascular disease (4, 5) , their clinical use has been limited by the concomitant blockade of the epithelial (renal, colonic) MR with the consequent development of significant hyperkalemia (6) . The identification of mechanisms of ligand discrimination at the MR, as for the other steroid receptors, is thus a desirable therapeutic goal. In the current study, we identified tesmin as a ligand-selective coactivator of the MR.
Tesmin coactivated the full-length MR bound to either aldosterone or DOC, but not when bound to cortisol. In the cotransfection assay, DOC exhibited properties equivalent to those of aldosterone. The response of the MR to aldosterone in the presence or absence of tesmin was, not unexpectedly, blocked by spironolactone. Spironolactone has been described as a passive antagonist (51) , and in most assays, it acts as a very weak agonist when administered alone (45, 46) . This agonist activity of spironolactone was enhanced by tesmin, which is an interesting contrast with cortisol. Interestingly, tesmin appeared to be a better coactivator for the MR than for the AR and did not coactivate the ER␣ GR or PR; however, in each case, only one ligand was examined. Given the ligand specificity of the coactivation by tesmin for the MR, it may be revealing to examine the response to a range of ligands at each of these other steroid receptors.
There are several examples of the importance of the promoter to MR transactivation and to coactivation (12) . To explore this issue, we examined the effect of tesmin coexpression in the context of the promoters derived from 2 physiological aldosterone-regulated genes, GILZ and CNKSR3, in addition to the MMTV Aldosterone   Cortisol   0nM  10nMAldo  100nMCor  0nM  10nMAldo  100nMCor  0nM  10nMAldo  100nMCor  0nM  10nMAldo  100nMCor  0nM  10nMAldo Fig. 1 for the M2H assay with the pVP16 vector alone, the pVP16-tesmin expression vector, or the pVP16-tesmin expression vector containing mutations in the first (M1), second (M2), or both (M1ϩM2) LxxLL motifs.
Response is expressed relative to pV16 vector alone with 10 nM aldosterone (meansϮsem). For tesmin and tesmin-M1 and -M2, the response to ligand is significantly greater than with vehicle alone. When tesmin-M1 ϩ M2 was compared to empty vector, the response to both ligands was significantly decreased. Autoradiogram is a Western blot with a VP-16 antibody, which confirms equivalent expression of the VP-16 tesmin wild-type and mutant plasmids. *P Ͻ 0.01 vs. tesmin with same concentration of ligand. Right panels: transactivation assay. CV-1 cells were transiently transfected as in Fig. 2 with the expression vector pSG5 alone, or the expression vector containing tesmin or tesmin containing one (M1 or M2) or both (M1ϩM2) mutant LxxLL motifs. Response was determined in the presence of 0, 1, 10, or 100 nM ligand, as indicated. Results are expressed relative to empty vector alone in the absence of ligand (meansϮsem). At each concentration of aldosterone, the response is significantly greater than vehicle alone for a given tesmin/mutant tesmin. With cortisol, the response is only significant at 100 nM. In addition, when the mutation-containing tesmin vectors are compared to vector alone at the same concentration of ligand, all are either not significantly different or are lower, except for tesmin-M2 with aldosterone.
Autoradiogram is a Western blot showing equivalent expression levels for the wild-type and mutant HA-tagged tesmin. *P Ͻ 0.01 vs. wild-type tesmin at same concentration of ligand.
promoter, which is conventionally used in the analysis of MR-mediated transactivation. In both cases, we observed coactivation of aldosterone-induced MR activation but not of cortisol-mediated activation by tesmin. The co-IP assays, taken in the context of the other analyses, argue for a direct interaction between the MR and tesmin in the presence of aldosterone, but not of cortisol. This finding was consistent with the initial Y2H screen, which suggested a binary interaction or noninteraction: aldosterone vs. cortisol. However, in the more quantitative M2H screen, there was a relative enrichment of the interaction mediated by aldosterone when compared to cortisol, suggesting that the difference is not so absolute. This dichotomy, aldosterone vs. cortisol, was not seen in either the Y2H or M2H with the known MR coactivators; PGC-1␣ and SRC-1. As noted, the equivalence of both ligands for SRC-1 and PGC-1␣ in the Y2H assay argues against an effect of either altered ligand-affinity and/or altered ligand efflux in the yeast system (42, 43) . The findings with the M2H assay further supports the hypothesis that ligandspecific or -enriched interactions can be identified for the MR-LBD.
Tesmin or MTL5 was first identified in the mouse as a testis-specific MTL protein and as a marker of male germ cell differentiation (44) . MTL proteins are highly conserved low-molecular-weight cysteine-rich proteins that are induced by heavy metal ions. They also bind heavy metals and are not thought to exhibit enzymatic activity. Two transcript variants of tesmin have been identified: variant 1 encodes the larger isoform a, and variant 2 encodes isoform b, which is shorter at the C terminus. The region encoded by the clone isolated from the Y2H screen is contained within both isoforms.
Isoform a, but not isoform b, contains 2 tesmin/TSO1-like CXC cysteine-rich domains that bind zinc (52) . Tesmin transcripts were subsequently reported in mouse fetal ovary, fetal testis, and adult heart (543). A human homologue has been identified (44) ; the gene is also called MTL5, MTLT, CXCDCZ, or LOC9633. Although there is only 1 published report that relates to the expression of tesmin outside the gonads, which found tesmin expression in gastric cancer (54) , ESTs for tesmin are found in a wide range of tissues, albeit at relatively low levels of expression. Although tesmin is generally thought to reside in the cytoplasm, in a study of the role of tesmin in spermatogenesis, Sutou et al. (55) reported that oxidative stress (cobalt chloride, diethylmaleate) leads to translocation of tesmin from the cytoplasm to the nucleus, a phenomenon also observed by Matsuura et al. (56) using cadmium and consistent with a recent study by Khanna et al. (57) .
The possibility that MR signaling might be modulated by heavy metal acting via the coactivator tesmin is both intriguing and unexpected. There is a growing body of literature (reviewed in ref. 58) suggesting that oxidative stress plays a role in activation of the MR, raising the possibility that tesmin contributes to the amplification of MR signaling during oxidative stress. This effect may be mediated through translocation of tesmin from the cytoplasm to the nucleus (55, 56) . Disordered zinc homeostasis has been reported to occur after chronic aldosterone treatment and in heart failure (59), suggesting a way in which the mineralocorticoid response may be modulated by zinc in the pathophysiology of cardiovascular disease. Conversely, it is conceivable that tesmin increases the specificity of aldosterone vs. cortisol in certain tissues, thereby further enforcing the prereceptor specificity provided, at least in epithelial and vascular tissues, by 11␤HSD2. Both isoforms of tesmin contain 2 LxxLL motifs that contribute to the interaction with the MR and its coactivator activity. The LxxLL motif is a feature of the interaction of many nuclear receptor coactivators with the AF-2 region of the receptor (38) . The 2 motifs in tesmin do not correspond to any of these 4 classes. The presence of 2 motifs in a coactivator is common and is associated with stronger interactions between the receptor and the coactivator (38) . Multiple copies of the motif have been interpreted as evidence that the coactivator may bridge 2 or more receptor monomers, consistent with the concept that the MR binds as a dimer.
The structural basis of this ligand-mediated discrimination is likely to be determined by the conformation and relationship of the 3 helices (3, 4, and 12) that form the groove into which the LxxLL motifs of the coactivator bind. Although the currently published crystal structures for the MR-LBD (29, 51, 60) do not reveal the different conformation that may be induced by aldosterone vs. cortisol in this region, it is clear from other studies using chimeric and/or mutated MR-LBD that their interactions are not equivalent. The 18-OH group of aldosterone is thought (51) to interact with Asn770 in helix 3, a stabilizing interaction that cannot occur with cortisol. Li et al. (29) reported that when corticosterone is bound in the MR-LBD, Asn770 forms a hydrogen bond with the C-ring 11-hydroxyl; a fundamentally different set of interactions from that seen with aldosterone (51), which could be predicted to produce subtle but significant differences in the orientation of the critical helices, particularly helix 3.
The structural basis of the tesmin-mediated coactivation is not clear. The shorter isoform lacks the zincbinding domain, yet mediates the ligand-discriminating coactivation, implying that the activation function resides in that portion of the molecule, although no known motifs, aside from the 2 LxxLL motifs, have been identified in this region (Fig. 2) . The repression of MR-mediated transactivation by the tesmin LxxLL double mutant (Fig. 7) is perplexing. Whether it is acting as an indirect repressor of the MR or it forms a nonproductive interaction with the transcriptional apparatus remains to be determined.
Although these results provide compelling evidence for ligand-discriminant coactivation of the MR by a novel coactivator, the physiological context and significance has yet to be discovered. The number of suitable model systems in which interactions of the endogenous MR and the coactivator of interest can be examined is extremely limited. Future studies of this interaction should exploit technologies such as chromatin immunoprecipitation of endogenous tesmin with the MR to explore the interaction on chromatin in a physiological context. Previous studies have failed to identify liganddiscriminant interactions with the MR AF-2 (28, 29) .
In summary, we successfully used a Y2H screen to isolate a ligand-discriminant MR coactivator. Although the physiological significance of this observation is unclear, it provides further evidence that, as for the AR (61), novel and unique coactivators exist outside of those characterized for interactions with the other steroid receptors, and they provide a potential pathway to the identification of selective MR modulators. Subsequent studies of the tesmin-mediated coactivation of the MR should address the spatial relationship across various tissues of the MR and tesmin, as well as explore the possible role that heavy metals play in the response.
OLIGONUCLEOTIDE PRIMER SEQUENCES TESMIN LxxLL MOTIF MUTAGENESIS Primer name
Description Direction Sequence M1 mutation of tesmin (LeuLeu 128/9) →AlaAla forward 5' GCA CTT CCT GTC CTC GGC GGC ACC CGC GCA CCG CAG C 3' M1 mutation of tesmin (LeuLeu 128/9) →AlaAla reverse 5' GCT GCG GTG CGC GGG TGC CGC CGA GGA CAG GAA GTG C 3' M2 mutation of tesmin (LeuLeu180/1) →AlaAla forward 5' GCA ACT TTG CAG AAT GCT GCT GCT CAG GAA TCC TGT TGC AAG TTC C 3' 
Supplementary Figure 4
Western blot analysis for the MR . Autoradiogram showing the result for the MR with vehicle (V), cortisol (Cort: 10nM) or aldosterone (Aldo: 10nM) in the presence of empty vector (pSG5) or tesmin using the monoclonal antibody, MR1-18 (a gift from Professor Celso Gomez-Sanchez).
